LONDON, UK, 4 March 2025 - In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumours (NETs), a ...
Frances Johnson, a medical doctor and chief innovation officer at Perspective Therapeutics, and Michael Schultz, a Ph.D. and the company’s chief science officer, are shown Oct. 1 at the company’s ...
Co-locating Convergent's manufacturing at NorthStar establishes an integrated and reliable supply chain for CONV01-<ALPHA> drug product production with Ac-225, relieving supply constraints for ...
Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation therapy that is delivered into or very close to the tumor. However, it is unknown whether the ...
Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to ...
Perspective Therapeutics' pipeline, led by VMT-a-NET, shows promising safety and early efficacy, but lacks clear superiority over existing therapies like Lutathera so far. The company maintains a ...
SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that it has entered into a patent license agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback